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What is the role of tacrolimus 
and pimecrolimus in atopic dermatitis?
■ Evidence summary
A recent meta-analysis included 25 ran-
domized controlled trials involving
tacrolimus and pimecrolimus.1 This review
included trials of tacrolimus and pime-
crolimus in comparison with placebo, top-
ical corticosteroids of varying strengths,
and each other. They reported on both
safety and efficacy. Fifteen vehicle-
controlled trials of pimecrolimus and
tacrolimus were reviewed. Both medica-
tions proved to be significantly more 
effective than the vehicle alone. A total of
3 trials (732 patients) compared
tacrolimus 0.1% with potent topical corti-
costeroids (hydrocortisone butyrate 0.1%,
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When the standard therapies—mild topical 
corticosteroids and moisturizers—fail in the 
treatment of atopic dermatitis, patients are left with
few proven remedies. The recently introduced 
topical immunosuppressive treatments—
pimecrolimus and tacrolimus—offer an alternative
to topical corticosteroids. 
Tacrolimus 0.1% (Protopic) appears to be both
safe and effective in treating eczema in adults and
children (strength of recommendation [SOR]: A). In
multiple studies, it has been as effective as potent
topical corticosteroids and more effective than
mild topical corticosteroids (SOR: A). 
Pimecrolimus (Elidel) is more effective than
placebo but less effective than potent topical 
corticosteroids (SOR: A). At this time, no data 
compare pimecrolimus with mild corticosteroids. 
It is important to note that while the studies
with the topical immunosuppressive agents 
included patients with mild to severe atopic 
dermatitis, none assessed the use of these agents
on patients with steroid-refractory atopic dermatitis.
The US Food and Drug Administration (FDA) 
has recommended limited use of these agents 
in atopic dermatitis because of potential cancer
risk (SOR: C).
E V I D E N C E - B A S E D A N S W E R
Benefits of topical immunosuppressants
don’t overcome cost and risks
This Clinical Inquiry is an excellent example of
how evidence has to be used in a broader context
when making clinical decisions, and how evidence
is critical in evaluating both benefits and risks of
treatments. There seems to be strong evidence
that topical immunosuppressants are at least as
good as topical steroids, but not better. They
apparently do not have a lower risk of infection.
We are then left with the only potential benefits
being that of not causing HPA axis suppression
and possibly not causing skin thinning. 
However, this seems to be a small benefit for
the enormous cost of these products (more than
$60 for a 30-g tube) as well as increased burning
on application. In the end, this is all trumped by
the recent FDA Advisory warning of a potential
cancer risk and advising use only as second-line
agents and for short intermittent periods. The 
practical answer to this question, therefore, is to
use the decades-old treatment of higher potency
topical steroids with prudence.
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beta-methasone valerate 0.1%) and found
it to be as effective as the topical steroids
after 3 weeks of application (number need-
ed to treat [NNT]=6).2,3
At both the 0.03% and 0.1%
strengths, tacrolimus was found to be
more effective than mild topical cortico-
steroids (hydrocortisone acetate 1%) in 
2 studies enrolling a total of 1183 children
with moderate to severe atopic dermatitis4,5
(NNT=5 for the tacrolimus 0.03%, and
NNT= 3 for tacrolimus 0.1%).6 A 
randomized, double-blinded, multicenter
trial compared the use of pimecrolimus
1% cream with 0.1% triamcinolone ace-
tonide cream and 1% hydrocortisone
acetate cream for 658 adults with moder-
ate-to-severe atopic dermatitis.7 The
majority of patients used either form of
treatment for 1 year. 
Although long-term safety and tolera-
bility were similar, topical corticosteroids
were more efficacious (NNT=13). Another
study compared pimecrolimus 1% with
betamethasone valerate 0.1% (a potent
corticosteroid) in a study of 87 patients.8
At the end of 3 weeks, the pimecrolimus
1% cream was significantly less effective
than betamethasone valerate 0.1%
(NNT=4).
In a meta-analysis of 3 randomized
studies of head-to-head comparison of
pimecrolimus 1% and tacrolimus 0.03%
or 0.1% among children and adults,
tacrolimus ointment was more effective
than pimecrolimus cream at the end of the
study for adults (P<.0001), for children
with moderate-to-severe disease (P=.04),
in the combined analysis (P<.0001), and at
week 1 for children with mild disease
(P=.04). No significant difference was seen
in the incidence of adverse effects,
although more pimecrolimus-treated
patients withdrew from the studies because
of a lack of efficacy (P≤.03) or adverse
events (P=.002; pediatric mild).9
The authors of the first meta-analysis
concluded that pimecrolimus 1% was more
effective compared with placebo, less effec-
tive than potent topical corticosteroids, 
and had yet to be studied in comparison
with low-potency topical corticosteroids.
Tacrolimus 0.1% was more effective than
placebo, more effective than mild corticos-
teroids, and as effective as potent topical
corticosteroids. It was noted that both these
agents caused more burning of the skin
than topical corticosteroids—pimecrolimus
1% compared with betamethasone valerate
0.1% (number needed to harm
[NNH]=50); tacrolimus 0.1% compared
with betamethasone valerate 0.1% and
hydrocortisone butyrate 0.1% (NNH=3);
and tacrolimus 0.03% compared with the
mild corticosteroid hydrocortisone acetate
1% (NNH=10). However, there was no
significant difference in the rate of skin
infections. 
Recommendations from others
In 2003, a work group of dermatologists
appointed by the president of the
American Academy of Dermatology pub-
lished a technical report on the guidelines
of care for atopic dermatitis.10 This group
evaluated the effectiveness of several topi-
cal treatments for the treatment of atopic
dermatitis. They noted that coal tar and
its derivatives may reduce the severity of
atopic dermatitis symptoms, but there are
significant barriers to compliance. The
severity of pruritus associated with atopic
dermatitis may be reduced with short-
term use of topical doxepin. 
Evidence supports the use of emol-
lients in combination with other topical
corticosteroid treatments to reduce the
severity of atopic dermatitis. However,
emollients need frequent application,
which may be associated with poor 
compliance. The work group also 
concluded that both tacrolimus and pime-
crolimus are effective and safe in reducing
the severity of atopic dermatitis symptoms
for both children and adults up to 1 year
of treatment. 
In March 2005, the FDA posted a
Public Health Advisory and Alerts for
Healthcare Professionals regarding the
potential cancer risk from the use
tacrolimus and pimecrolimus products
when applied to the skin to treat atopic
The FDA has 
posted a Public
Health Advisory
regarding the
potential cancer
risk from these
products when
used to treat
atopic dermatitis
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dermatitis. These creams will carry a
“black box” warning regarding this poten-
tial risk. They recommended use only as a
second-line therapy, at minimal amounts
necessary, and for short periods of time,
not continuously. They also recommended
against their use for children aged <2 years
and for people with diminished immune
systems.
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CLINICAL INQUIRIES
■ What blood tests will help 
diagnose celiac disease?
■ How should patients with 
Barrett’s esophagus be monitored?
■ What is the best method 
of detecting herpes in skin lesions?
■ Is increased fall risk 
a significant predictor 
of major bleeding events 
in patients on warfarin?
■ What are effective treatments 
for oppositional defiant behaviors
in adolescents?
■ What are the indications 
for endoscopy in elderly patients
with symptoms suggesting GERD?
■ What anxiolytics are safe 
for use while breastfeeding?
■ What factors predict a successful
smoking cessation attempt?
Look for these topics in
Clinical Inquiries
Coming soon in JFP
